Emulate
Business Services · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
27 Drydock Ave Ste 5, Boston, Massachuse...Phone Number
(781) 583-3515Website
www.emulatebio.comRevenue
$13 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
2
1
3
1
1
About Emulate
Established in 2013, Emulate is headquartered in Boston, Massachusetts. They are a startup company that is commercializing Organs-on-Chips technologya human cell-based technology that recreates organ-level function to model organs in healthy and diseased states.Explore more
Emulate Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Emulate your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Emulate launches new products
Congratulate Masked Content for being promoted to Masked Content at Emulate
Emulate, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Emulate recently announced quarterly report
Funding: Get notified immidiatlly once Emulate has new funding data
Click to see if Emulate had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check out if Emulate is spiking on competitors!
Check if Emulate has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Emulate
Compare insights from companies similar to Emulate, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Emulate is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Emulate is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Emulate.
Emulate financials insights
Gather financial insights about Emulate, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Series A
$12M
2016
Series B
$17M
2017
Grant
$2M
Private Equity
$745K
2018
Series C
$36M
2020
Other Financing Round
$19.3M
2021
Series E
$82M
Emulate Tech Stack
A closer look at the technologies used by Emulate
See more technologies
Most Recent Scoops
Event
Product Marketing, Events, Research & Development, Bioengineering, Medical Research, Clinical Operations, Healthcare Technology
Open Position
Open Position
Open Position
Open Position
Emulate News & Media
Emulate Publishes Novel Framework to Pave the Way for the Integration of Liver-Chip Technology into Pharmaceutical Safety Assessment
BOSTON--(BUSINESS WIRE)--Emulate, Inc., the leading provider of next-generation in vitro models, today announced the publication “Integrating Liver-Chip Data into Pharmaceutical Decision-Making Processes” in Expert Opinion on Drug Discovery. The article introduces a decision-making framework that includes two guidelines for researchers to use in their safety assessment workflows to identify drug-induced liver injury (DILI) risk, improving patient safety and supporting the 3R goals of reducing aEmulate Unveils Chip-A1, Expanding Organ-on-a-Chip Technology Applications Within the Cancer and Cosmetics Markets
BOSTON--(BUSINESS WIRE)--Emulate, Inc., the leading provider of next-generation in vitro models, today announced the launch of the Emulate Chip-A1™ Accessible Chip through an early access program. This new Organ-Chip design expands on the original Chip-S1—which models tissue-vascular interfaces with relevant biomechanical forces such as stretch and flow—by allowing users to create thicker tissues within the epithelial culture chamber and apply additional drug treatment options, including topicaEmulate Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2023
BOSTON--(BUSINESS WIRE)--Emulate, Inc., a leading provider of next-generation in vitro models, today announced that it has been named to Fast Company’s prestigious annual list of the World’s Most Innovative Companies for 2023. This year’s list highlights the businesses who are setting the standard in their respective industries. In addition to the World’s 50 Most Innovative Companies, 540 organizations are recognized across 54 sectors and regions. “To once again be among this distinguished grouEmulate Announces Inaugural Global MPS Day and Virtual Symposium to Raise Awareness of Animal Model Alternatives in Scientific Research
BOSTON--(BUSINESS WIRE)--Emulate, Inc., the leading provider of next-generation in vitro models, today announced Global MPS Day. Taking place on March 9, 2023, this day is dedicated to fostering community relationships and raising awareness of the growing number of microphysiological systems (MPS) being used in drug discovery and development. To support this inaugural day, Emulate will host a three-hour, virtual symposium focused on advancements within MPS and Organ-on-a-Chip technology with Ro
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Emulate
Sign Up For FreeTo access detailed company insights
Established in 2013, Emulate is headquartered in Boston, Massachusetts. They are a startup company that is commercializing Organs-on-Chips technologya human cell-based technology that recreates organ-level function to model organs in healthy and diseased states.... Read More
